{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:34Z","timestamp":1786982134327,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11910-025-01446-2","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T07:35:07Z","timestamp":1754724907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Psychedelics and Headache Disorders: an Update"],"prefix":"10.1007","volume":"25","author":[{"given":"James J.H.","family":"Im","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1904-2406","authenticated-orcid":false,"given":"Claire H.","family":"Sandoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"issue":"4","key":"1446_CR1","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/ALN.0000000000004673","volume":"139","author":"A Goel","year":"2023","unstructured":"Goel A, Rai Y, Sivadas S, Diep C, Clarke H, Shanthanna H, et al. Use of psychedelics for pain: A scoping review. Anesthesiology. 2023;139(4):523\u201336.","journal-title":"Anesthesiology"},{"key":"1446_CR2","doi-asserted-by":"publisher","first-page":"109166","DOI":"10.1016\/j.neuropharm.2022.109166","volume":"215","author":"EAD Schindler","year":"2022","unstructured":"Schindler EAD. Psychedelics as preventive treatment in headache and chronic pain disorders. Neuropharmacology. 2022;215:109166.","journal-title":"Neuropharmacology"},{"issue":"9","key":"1446_CR3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40263-024-01107-x","volume":"38","author":"EAD Schindler","year":"2024","unstructured":"Schindler EAD. Psychotropic drugs reemerging as headache medicines. CNS Drugs. 2024;38(9):661\u201370.","journal-title":"CNS Drugs"},{"issue":"10","key":"1446_CR4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/head.14420","volume":"62","author":"EAD Schindler","year":"2022","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Zhu Y, et al. Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial. Headache. 2022;62(10):1383\u201394.","journal-title":"Headache"},{"issue":"10","key":"1446_CR5","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/14737175.2023.2246655","volume":"23","author":"EAD Schindler","year":"2023","unstructured":"Schindler EAD, Hendricks PS. Adapting psychedelic medicine for headache and chronic pain disorders. Expert Rev Neurother. 2023;23(10):867\u201382.","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"1446_CR6","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1111\/j.1526-4610.2007.00776.x","volume":"47","author":"M Denuelle","year":"2007","unstructured":"Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G. Hypothalamic activation in spontaneous migraine attacks. Headache J Head Face Pain. 2007;47(10):1418\u201326.","journal-title":"Headache J Head Face Pain"},{"issue":"1","key":"1446_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/head.14656","volume":"64","author":"MK Madsen","year":"2024","unstructured":"Madsen MK, Petersen AS, Stenb\u00e6k DS, S\u00f8rensen IM, Schi\u00f8nning H, Fjeld T, et al. CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity. Headache J Head Face Pain. 2024;64(1):55\u201367.","journal-title":"Headache J Head Face Pain"},{"issue":"4","key":"1446_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/02791072.1985.10524332","volume":"17","author":"AA Kurland","year":"1985","unstructured":"Kurland AA. LSD in the supportive care of the terminally ill cancer patient. J Psychoact Drugs. 1985;17(4):279\u201390.","journal-title":"J Psychoact Drugs"},{"issue":"4","key":"1446_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/papr.13203","volume":"23","author":"NI Kooijman","year":"2023","unstructured":"Kooijman NI, Willegers T, Reuser A, Mulleners WM, Kramers C, Vissers KCP, et al. Are psychedelics the answer to chronic pain: A review of current literature. Pain Pract. 2023;23(4):447\u201358.","journal-title":"Pain Pract"},{"key":"1446_CR10","doi-asserted-by":"publisher","unstructured":"Liechti ME, Holze F. Dosing Psychedelics and MDMA. In: Barrett FS, Preller KH, editors. Disruptive Psychopharmacology [Internet]. Cham: Springer International Publishing; 2021 [cited 2024 Dec 29]. pp. 3\u201321. (Current Topics in Behavioral Neurosciences; vol. 56). Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/7854_2021_270","DOI":"10.1007\/7854_2021_270"},{"issue":"5","key":"1446_CR11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1080\/02791072.2015.1107664","volume":"47","author":"EAD Schindler","year":"2015","unstructured":"Schindler EAD, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine hallucinogens in cluster headache: results of the clusterbusters medication use survey. J Psychoact Drugs. 2015;47(5):372\u201381.","journal-title":"J Psychoact Drugs"},{"issue":"9","key":"1446_CR12","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1177\/0333102410363490","volume":"30","author":"M Karst","year":"2010","unstructured":"Karst M, Halpern JH, Bernateck M, Passie T. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia. 2010;30(9):1140\u20134.","journal-title":"Cephalalgia"},{"issue":"6","key":"1446_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1001\/archneurpsyc.1957.02330420113020","volume":"78","author":"LD Clark","year":"1957","unstructured":"Clark LD. Psychopharmacological studies of lysergic acid diethylamide (LSD-25) intoxication: effects of premedication with BOL-128 (2-Bromo-d-Lysergic acid diethylamide), Mescaline, Atropine, Amobarbital, and Chlorpromazine. AMA Arch Neurol Psychiatry. 1957;78(6):653.","journal-title":"AMA Arch Neurol Psychiatry"},{"issue":"5","key":"1446_CR14","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.7326\/0003-4819-48-5-1078","volume":"48","author":"N Richards","year":"1958","unstructured":"Richards N, Chapman LF, Goodell H, Wolff HG, LSD-like delirium following ingestion of a small amount of its brom analog (BOL-148). Ann Intern Med. 1958;48(5):1078\u201383.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1446_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1176\/ajp.116.3.261","volume":"116","author":"WJ Turner","year":"1959","unstructured":"Turner WJ, Almudevar M, Merlis S, Chemotherapeutic trials in psychosis III. Addendum: 2-Brom-d-Lysergic acid diethylamide (BOL). Am J Psychiatry. 1959;116(3):261\u20132.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"1446_CR16","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","volume":"47","author":"DC D\u2019Souza","year":"2022","unstructured":"D\u2019Souza DC, Syed SA, Flynn LT, Safi-Aghdam H, Cozzi NV, Ranganathan M. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2022;47(10):1854\u201362.","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"issue":"8","key":"1446_CR17","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/02698811241246857","volume":"38","author":"JJ Rucker","year":"2024","unstructured":"Rucker JJ, Roberts C, Seynaeve M, Young AH, Suttle B, Yamamoto T, et al. Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered States of consciousness of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine benzoate) in healthy participants. J Psychopharmacol (Oxf). 2024;38(8):712\u201323.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"1446_CR18","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"1","key":"1446_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-023-01660-8","volume":"24","author":"NLT Lund","year":"2023","unstructured":"Lund NLT, Petersen AS, Fronczek R, Tfelt-Hansen J, Belin AC, Meisingset T, et al. Current treatment options for cluster headache: limitations and the unmet need for better and specific treatments-a consensus Article. J Headache Pain. 2023;24(1):121.","journal-title":"J Headache Pain"},{"issue":"1","key":"1446_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/jnnp.2003.024240","volume":"76","author":"MS Matharu","year":"2005","unstructured":"Matharu MS. Verapamil induced gingival enlargement in cluster headache. J Neurol Neurosurg Psychiatry. 2005;76(1):124\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"1446_CR21","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","volume":"66","author":"RA Sewell","year":"2006","unstructured":"Sewell RA, Halpern JH, Pope HG. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66(12):1920\u20132.","journal-title":"Neurology"},{"issue":"2","key":"1446_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1177\/0333102415583145","volume":"36","author":"C Di Lorenzo","year":"2016","unstructured":"Di Lorenzo C, Coppola G, Di Lorenzo G, Bracaglia M, Rossi P, Pierelli F. The use of illicit drugs as self-medication in the treatment of cluster headache: results from an Italian online survey. Cephalalgia. 2016;36(2):194\u20138.","journal-title":"Cephalalgia"},{"issue":"5","key":"1446_CR23","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1177\/0333102418804160","volume":"39","author":"IF De Coo","year":"2019","unstructured":"De Coo IF, Naber WC, Wilbrink LA, Haan J, Ferrari MD, Fronczek R. Increased use of illicit drugs in a Dutch cluster headache population. Cephalalgia. 2019;39(5):626\u201334.","journal-title":"Cephalalgia"},{"issue":"4","key":"1446_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/02791072.2020.1762023","volume":"52","author":"S Johnson","year":"2020","unstructured":"Johnson S, Black QC. Can psychedelics alleviate symptoms of cluster headache and accompanying mental health problems?? A case report involving Hawaiian baby Woodrose. J Psychoact Drugs. 2020;52(4):319\u201323.","journal-title":"J Psychoact Drugs"},{"key":"1446_CR25","doi-asserted-by":"publisher","first-page":"122993","DOI":"10.1016\/j.jns.2024.122993","volume":"460","author":"EAD Schindler","year":"2024","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Flynn LT, Zhu Y, Pittman BP, et al. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. J Neurol Sci. 2024;460:122993.","journal-title":"J Neurol Sci"},{"key":"1446_CR26","unstructured":"De Freitas Dias B, Robinson CL, Villar-Martinez MD, Ashina S, Goadsby PJ. Current and Novel Therapies for Cluster Headache: A Narrative Review. Pain Ther [Internet]. 2024 Nov 3 [cited 2024 Dec 28]; Available from: https:\/\/link.springer.com\/10.1007\/s40122-024-00674-7"},{"issue":"10","key":"1446_CR27","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/head.14837","volume":"64","author":"J Rucker","year":"2024","unstructured":"Rucker J, Butler M, Hambleton S, Bird C, Seynaeve M, Cheema S, et al. Low-dose psilocybin in short\u2010lasting unilateral neuralgiform headache attacks: results from an open\u2010label phase Ib ascending dose study. Headache J Head Face Pain. 2024;64(10):1309\u201317.","journal-title":"Headache J Head Face Pain"},{"issue":"5","key":"1446_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/head.14722","volume":"64","author":"J Leighton","year":"2024","unstructured":"Leighton J, Petignat C, McGeeney BE. Suspension of Short-lasting, unilateral, neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) symptoms with Ayahuasca and serotonergic psychedelics. Headache J Head Face Pain. 2024;64(5):595\u20137.","journal-title":"Headache J Head Face Pain"},{"key":"1446_CR29","first-page":"116","volume":"6","author":"F Sicuteri","year":"1963","unstructured":"Sicuteri F, Prophylactic treatment of migraine by, means of lysergic acid derivatives. Triangle Sandoz J Med Sci. 1963;6:116\u201325.","journal-title":"Triangle Sandoz J Med Sci"},{"issue":"9","key":"1446_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11916-023-01145-y","volume":"27","author":"EAD Schindler","year":"2023","unstructured":"Schindler EAD. The potential of psychedelics for the treatment of episodic migraine. Curr Pain Headache Rep. 2023;27(9):489\u201395.","journal-title":"Curr Pain Headache Rep"},{"issue":"2","key":"1446_CR31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/02791072.2019.1593561","volume":"51","author":"J Fadiman","year":"2019","unstructured":"Fadiman J, Korb S. Might microdosing psychedelics be safe and beneficial? An initial exploration. J Psychoact Drugs. 2019;51(2):118\u201322.","journal-title":"J Psychoact Drugs"},{"issue":"7\u20139","key":"1446_CR32","first-page":"37","volume":"20","author":"DW Lawrence","year":"2023","unstructured":"Lawrence DW. Self-administration of psilocybin for the acute treatment of migraine: A case report. Innov Clin Neurosci. 2023;20(7\u20139):37\u20139.","journal-title":"Innov Clin Neurosci"},{"issue":"1","key":"1446_CR33","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","volume":"18","author":"EAD Schindler","year":"2021","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, et al. Exploratory controlled study of the Migraine-Suppressing effects of psilocybin. Neurotherapeutics. 2021;18(1):534\u201343.","journal-title":"Neurotherapeutics"},{"issue":"6","key":"1446_CR34","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1177\/20494637221114962","volume":"16","author":"V Bonnelle","year":"2022","unstructured":"Bonnelle V, Smith WJ, Mason NL, Cavarra M, Kryskow P, Kuypers KP, et al. Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey. Br J Pain. 2022;16(6):619\u201331.","journal-title":"Br J Pain"},{"key":"1446_CR35","doi-asserted-by":"publisher","first-page":"735427","DOI":"10.3389\/fpsyt.2021.735427","volume":"12","author":"J Bornemann","year":"2021","unstructured":"Bornemann J, Close JB, Spriggs MJ, Carhart-Harris R, Roseman L. Self-Medication for chronic pain using classic psychedelics: A qualitative investigation to inform future research. Front Psychiatry. 2021;12:735427.","journal-title":"Front Psychiatry"},{"issue":"6","key":"1446_CR36","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol (Oxf). 2008;22(6):603\u201320.","journal-title":"J Psychopharmacol (Oxf)"},{"issue":"11","key":"1446_CR37","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/j.1468-2982.2008.01648.x","volume":"28","author":"P Koehler","year":"2008","unstructured":"Koehler P, Tfelt-Hansen P. History of methysergide in migraine. Cephalalgia. 2008;28(11):1126\u201335.","journal-title":"Cephalalgia"},{"issue":"12","key":"1446_CR38","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","volume":"81","author":"JT Hinkle","year":"2024","unstructured":"Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse events in studies of classic psychedelics: A systematic review and Meta-Analysis. JAMA Psychiatry. 2024;81(12):1225.","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"1446_CR39","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1177\/10600280231205645","volume":"58","author":"D Kaminski","year":"2024","unstructured":"Kaminski D, Reinert JP. The tolerability and safety of psilocybin in psychiatric and Substance-Dependence conditions: A systematic review. Ann Pharmacother. 2024;58(8):811\u201326.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"1446_CR40","doi-asserted-by":"publisher","first-page":"e245960","DOI":"10.1001\/jamanetworkopen.2024.5960","volume":"7","author":"A Yerubandi","year":"2024","unstructured":"Yerubandi A, Thomas JE, Bhuiya NMMA, Harrington C, Villa Zapata L, Caballero J. Acute adverse effects of therapeutic doses of psilocybin: A systematic review and Meta-Analysis. JAMA Netw Open. 2024;7(4):e245960.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"1446_CR41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/02698811231154852","volume":"37","author":"J Sloshower","year":"2023","unstructured":"Sloshower J, Skosnik PD, Safi-Aghdam H, Pathania S, Syed S, Pittman B, et al. Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial. J Psychopharmacol (Oxf). 2023;37(7):698\u2013706.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"1446_CR42","doi-asserted-by":"publisher","first-page":"115880","DOI":"10.1016\/j.psychres.2024.115880","volume":"335","author":"B Romeo","year":"2024","unstructured":"Romeo B, Kervadec E, Fauvel B, Strika-Bruneau L, Amirouche A, Verroust V, et al. Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review. Psychiatry Res. 2024;335:115880.","journal-title":"Psychiatry Res"},{"issue":"2","key":"1446_CR43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/00048674241289024","volume":"59","author":"RR Freitas","year":"2025","unstructured":"Freitas RR, Gotsis ES, Gallo AT, Fitzgibbon BM, Bailey NW, Fitzgerald PB. The safety of psilocybin-assisted psychotherapy: A systematic review. Aust N Z J Psychiatry. 2025;59(2):128\u201351.","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"1446_CR44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","volume":"80","author":"JS Siegel","year":"2023","unstructured":"Siegel JS, Daily JE, Perry DA, Nicol GE. Psychedelic drug legislative reform and legalization in the US. JAMA Psychiatry. 2023;80(1):77.","journal-title":"JAMA Psychiatry"},{"key":"1446_CR45","unstructured":"Health Canada. (2024, April 3). Psilocybin and psilocin (Magic mushrooms). Canada.ca. https:\/\/www.canada.ca\/en\/health-canada\/services\/substance-use\/controlled-illegal-drugs\/magic-mushrooms.html"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01446-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-025-01446-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01446-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:46:32Z","timestamp":1757346392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-025-01446-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1446"],"URL":"https:\/\/doi.org\/10.1007\/s11910-025-01446-2","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"1 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"57"}}